Compass Inc. Class A Common Stock vs Definium Therapeutics Inc. Common Shares — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.71B). The key difference: Compass Inc. Class A Common Stock is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Compass Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Definium Therapeutics Inc. Common Shares for 0 Days on average.
| COMP | DFTX | |
|---|---|---|
Market Cap | $7.05B | $4.71B |
Volume | 15,310,192 | 1,966,636 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $48.45 |
52-Week Low | $6.68 | $10.68 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.47B | $3.67B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →